查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1574198

生命科学领域的人工智慧市场 - 2024 年至 2029 年预测

Artificial Intelligence (AI) in Life Sciences Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 119 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

生命科学领域的人工智慧市场规模预计将从 2024 年的 14.13 亿美元增加到 2029 年的 43.52 亿美元，预测期内复合年增长率为 25.23%。

生命科学是一个为了因应成本上升而转向更有效率方法的行业。在生命科学产业，人工智慧 (AI) 通常有助于从读取资料中识别关係，或产生有关工具工作方式的机械见解。生命科学领域人工智慧市场的显着成长归因于该领域产生的资料量不断增加。这些资料有助于为各种生命科学应用产生可预测且准确的见解。

此外，医学研究投资的增加正在促进新疗法的创建，这些疗法依赖更快、更有效的手段，让研究人员更容易存取重要的资料集。因此，越来越多地采用人工智慧服务来分析非结构化资料并得出与计划特定要求相关的见解，从而促进了市场扩张。

推动生命科学领域人工智慧市场的因素：

  • 药物发现支出的增加预计将加速全球生命科学领域对人工智慧的需求。

此外，药物研发的高昂成本进一步支持了人工智慧在生命科学领域的应用。因此，生命科学人工智慧市场的公司正在实施人工智慧技术，以降低成本并提高药物发现的成功机率。药物发现占与其相关成本的很大一部分。因此，需要降低药物发现的成本和时间并提高临床试验的成功率，这广泛影响了人工智慧技术在该行业的使用。

例如，2023 年 10 月，全球生物製药公司 Insmed 与 Google Cloud 合作，透过采用生成式 AI 彻底改变生命科学领域。此次合作的重点是减少新药发现并将其提供给患者的时间并提高效率。 InsMed 在严重罕见疾病方面的专业知识将被用来推进此方法。此次合作将针对生命科学产业的四个关键角度：药物发现、开发、商业化和能力建构。计划预计将在未来18个月内完成。

生命科学领域AI市场的地理前景：

  • 北美地区预计将在生命科学领域的人工智慧市场中占据很大份额。

由于先进技术的早期采用以及美国主要企业的存在，北美在全球生命科学人工智慧市场中显示出显着成长。由于中国是辉瑞（Pfizer）和强生（Johnson & Johnson）等全球製药公司的总部所在地，预计将成为药物开发和药物发现领域人工智慧解决方案传播的主要推动力。这些公司已经建立了自己的人工智慧部门或与多家人工智慧新兴企业合作，这可以帮助药物发现和病患监测。

此外，由于人工智慧技术资金的增加以及美国和加拿大等政府支援政策的增加，区域市场可能会出现提振，以便更好地在生命科学产业中采用该技术。美国政府正在推动资料共用，医疗保健人工智慧公司在这方面具有优势，可以用来製造个人化药物和治疗方法。

为什么要购买这份报告？

  • 富有洞察力的分析：获得涵盖关键和新兴地区的深入市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、行业部门和其他子区隔。
  • 竞争格局：了解世界主要企业采取的策略策略，并了解透过正确的策略渗透市场的潜力。
  • 市场驱动因素和未来趋势：探索动态因素和关键市场趋势以及它们将如何影响未来市场发展。
  • 可行的建议：利用洞察力做出策略决策，以在动态环境中发现新的业务流和收益。
  • 面向广大受众：对于新兴企业、研究机构、顾问、中小型企业和大型企业有用且具有成本效益。

公司使用我们的报告的目的是什么？

产业和市场考量、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2022年至2029年历史资料与预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争对手的市场状况、策略与市场占有率分析
  • 包括国家在内的细分市场和地区的收益成长和预测评估
  • 公司简介（策略、产品、财务资讯、主要动态等）

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章生命科学领域的人工智慧市场：透过提供

  • 介绍
  • 硬体
  • 软体
  • 服务

第六章生命科学领域的人工智慧市场：依应用分类

  • 介绍
  • 药物发现
  • 临床试验
  • 医学诊断
  • 个人化医疗
  • 其他的

第七章生命科学领域的人工智慧市场：按地区划分

  • 介绍
  • 北美洲
    • 按报价
    • 按用途
    • 按国家/地区
  • 南美洲
    • 按报价
    • 按用途
    • 按国家/地区
  • 欧洲
    • 按报价
    • 按用途
    • 按国家/地区
  • 中东/非洲
    • 按报价
    • 按用途
    • 按国家/地区
  • 亚太地区
    • 按报价
    • 按用途
    • 按国家/地区

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章 公司简介

  • IBM Corporation
  • Google
  • Microsoft Corporation
  • Concerto HealthAI
  • Atomwise, Inc.
  • CytoReason
  • Accenture
  • IKTOS
  • AiCure
  • NuMedii Inc
  • NVIDIA Corporation
  • A2A Pharma
简介目录
Product Code: KSI061613572

The AI in life sciences market is projected to witness a CAGR of 25.23% during the forecast period to reach a market size of US$4.352 billion by 2029, from US$1.413 billion in 2024.

Life sciences is one of the industries witnessing a push toward more productive methods in response to escalating costs. In the life sciences industry, Artificial Intelligence (AI) typically helps to identify relationships from read-across data or generate mechanistic insight about how a tool is working. The substantial growth of AI in the life sciences market is due to the increasing volume of data generated in this sector. This data assists in producing predictable and accurate insights across various applications within the life sciences field.

In addition, growing investments in medical research are driving the creation of new treatments that rely upon faster and more efficient means for researchers to reach essential data sets by making them easily accessible. This, in turn, is fueling an increasing adoption of AI services to analyze unstructured data and draw insights related to the specific requirements of the projects, propelling the market expansion.

AI IN LIFE SCIENCES MARKET DRIVERS:

  • Growing expenditure on drug discovery is predicted to accelerate the demand for AI in life science globally.

Additionally, the high costs of drug discovery are further supporting the use of AI in life sciences. Life sciences market players, therefore, deploy artificial intelligence technology to lower costs and increase the likelihood of success for drug discovery. Discovery consumes a significantly high proportion of the costs associated with it. Hence, decreasing cost and time in drug discovery & increasing clinical trial success rates are necessary and broadly influencing the usage of AI technology in this industry.

For instance, in October 2023, Insmed, a worldwide biopharmaceutical corporation, collaborated with Google Cloud to revolutionize the life sciences sector by employing generative AI. The association focuses on decreasing time and incrementing effectiveness in creating and delivering new medications to patients. Insmed's expertise in serious and rare illnesses will be utilized to progress the method. The collaboration will aim at four key life sciences industry angles: drug discovery, development, commercialization, and empowering capacities. Projects are anticipated to be completed within the following 18 months.

AI in Life Sciences Market Geographical Outlook:

  • The North American region is anticipated to hold a substantial AI in life sciences market share.

North America shows significant growth in the global AI in life sciences market due to the early adoption of advanced technologies and the presence of key players in the U.S. The country is experiencing a growing surge in demand for AI solutions within life sciences end-user verticals. The existence of global pharmaceutical companies such as Pfizer and Johnson & Johnson in the country is expected to be a key driver for the proliferation of AI solutions for R&D in drug development and discovery. These companies are creating their own AI departments or partnering with multiple AI start-ups, which could assist them in drug discovery and patient monitoring.

Additionally, the market in the regions will experience upliftment due to increased funding of AI technology and supportive government policies for better adoption of this technology in the life sciences industry, such as the USA and Canada. The US government is promoting data sharing, which gives its healthcare AI companies an edge and can be utilized for the manufacturing of personalized medication and treatment.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2029
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Market Segmentation:

The AI in Life Sciences Market is segmented and analyzed as below:

By Offering

  • Hardware
  • Software
  • Services

By Application

  • Drug Discovery
  • Clinical Trials
  • Medical Diagnosis
  • Personalized Medicine
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • Australia
  • India
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. AI IN LIFE SCIENCES MARKET BY OFFERING

  • 5.1. Introduction
  • 5.2. Hardware
  • 5.3. Software
  • 5.4. Services

6. AI IN LIFE SCIENCES MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Drug Discovery
  • 6.3. Clinical Trials
  • 6.4. Medical Diagnosis
  • 6.5. Personalized Medicine
  • 6.6. Others

7. 6. AI IN LIFE SCIENCES MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Offering
    • 7.2.2. By Application
    • 7.2.3. By Country
      • 7.2.3.1. USA
      • 7.2.3.2. Canada
      • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Offering
    • 7.3.2. By Application
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
      • 7.3.3.2. Argentina
      • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Offering
    • 7.4.2. By Application
    • 7.4.3. By Country
      • 7.4.3.1. Germany
      • 7.4.3.2. France
      • 7.4.3.3. United Kingdom
      • 7.4.3.4. Spain
      • 7.4.3.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. By Offering
    • 7.5.2. By Application
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
      • 7.5.3.2. Israel
      • 7.5.3.3. UAE
      • 7.5.3.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Offering
    • 7.6.2. By Application
    • 7.6.3. By Country
      • 7.6.3.1. China
      • 7.6.3.2. Japan
      • 7.6.3.3. South Korea
      • 7.6.3.4. Australia
      • 7.6.3.5. India
      • 7.6.3.6. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. IBM Corporation
  • 9.2. Google
  • 9.3. Microsoft Corporation
  • 9.4. Concerto HealthAI
  • 9.5. Atomwise, Inc.
  • 9.6. CytoReason
  • 9.7. Accenture
  • 9.8. IKTOS
  • 9.9. AiCure
  • 9.10. NuMedii Inc
  • 9.11. NVIDIA Corporation
  • 9.12. A2A Pharma